Información de la droga para Amlodipine besylate (Greenstone LLC): ADVERSE REACTIONS

Ads
  • Amlodipine besylate tablets have been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with amlodipine besylate tablets was well-tolerated at doses up to 10 mg daily. Most adverse reactions reported during therapy with amlodipine besylate tablets were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine besylate tablets (N=1730) in doses up to 10 mg to placebo (N=1250), discontinuation of amlodipine besylate tablets due to adverse reactions was required in only about 1.5% of patients and was not significantly different from placebo (about 1%). The most common side effects are headache and edema. The incidence (%) of side effects which occurred in a dose related manner are as follows:

    Adverse Event2.5 mgN=2755.0 mgN=29610.0 mgN=268PlaceboN=520
    Edema1.83.010.80.6
    Dizziness1.13.43.41.5
    Flushing0.71.42.60.0
    Palpitation0.71.44.50.6

    Other adverse experiences which were not clearly dose related but which were reported with an incidence greater than 1.0% in placebo-controlled clinical trials include the following:

    Placebo-Controlled Studies
    AMLODIPINE(%)(N=1730)PLACEBO(%)(N=1250)
    Headache7.37.8
    Fatigue4.52.8
    Nausea2.91.9
    Abdominal Pain1.60.3
    Somnolence1.40.6

    For several adverse experiences that appear to be drug and dose related, there was a greater incidence in women than men associated with amlodipine treatment as shown in the following table:

    AMLODIPINEPLACEBO
    Adverse EventMale=%(N=1218)Female=%(N=512)Male=%(N=914)Female=%(N=336)
    Edema5.614.61.45.1
    Flushing1.54.50.30.9
    Palpitations1.43.30.90.9
    Somnolence1.31.60.80.3

    The following events occurred in <1% but >0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:

    Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural hypotension, vasculitis.

    Central and Peripheral Nervous System: hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigo.

    Gastrointestinal: anorexia, constipation, dyspepsia,These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies. dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia.

    General: allergic reaction, asthenia, back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease.

    Musculoskeletal System: arthralgia, arthrosis, muscle cramps, myalgia.

    Psychiatric: sexual dysfunction (male and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization.

    Respiratory System: dyspnea, epistaxis.

    Skin and Appendages: angioedema, erythema multiforme, pruritus, rash, rash erythematous, rash maculopapular.

    Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus.

    Urinary System: micturition frequency, micturition disorder, nocturia.

    Autonomic Nervous System: dry mouth, sweating increased.

    Metabolic and Nutritional: hyperglycemia, thirst.

    Hemopoietic: leukopenia, purpura, thrombocytopenia.

    The following events occurred in <0.1% of patients: cardiac failure, pulse irregularity, extrasystoles, skin discoloration, urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, coughing, rhinitis, dysuria, polyuria, parosmia, taste perversion, abnormal visual accommodation, and xerophthalmia.

    Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as myocardial infarction and angina.

    Amlodipine besylate tablet therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine.

    In the CAMELOT and PREVENT studies (see CLINICAL PHARMACOLOGY Clinical Studies Studies in Patients with Coronary Artery Disease) the adverse event profile was similar to that reported previously (see above), with the most common adverse event being peripheral edema.

    The following postmarketing event has been reported infrequently where a causal relationship is uncertain: gynecomastia. In postmarketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis) in some cases severe enough to require hospitalization have been reported in association with use of amlodipine.

    Amlodipine besylate tablets have been used safely in patients with chronic obstructive pulmonary disease, well-compensated congestive heart failure, coronary artery disease, peripheral vascular disease, diabetes mellitus, and abnormal lipid profiles.

  • Drug Information Provided by National Library of Medicine (NLM).
Ads